Article, 2024

492TiP HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first-line treatment for HER2-positive esophageal squamous cell carcinoma patients

Annals of Oncology, ISSN 1569-8041, 0923-7534, Volume 35, Pages s195-s196, 10.1016/j.annonc.2024.05.404

Contributors

Egebjerg, Kristian 0000-0001-8781-8355 [1] Baeksgaard, Lene 0000-0003-4662-5164 [1] Garbyal, Rajendra Singh [1] Pfeiffer, Per 0000-0002-2925-0586 [2] Caterino, T. [2] Bjerregaard, Jon Kroll 0000-0003-1088-7242 [1] Yilmaz, M.N. [3] Wanders, Alkwin [3] Thorsen, L.B.J. [4] Hamilton-Dutoit, Stephen 0000-0003-2158-3885 [4] Ahlborn, Lise Barlebo 0000-0001-8021-7442 [1] Pallisgaard, Niels 0000-0002-0749-0810 [5] Mau-Sorensen, Paul Morten 0000-0003-2235-1250 [1]

Affiliations

  1. [1] Rigshospitalet
    2. [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
  2. [2] Odense University Hospital
    3. [NORA names: Region of Southern Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
  3. [3] Aalborg University Hospital
    4. [NORA names: North Denmark Region; Hospital; Denmark; Europe, EU; Nordic; OECD];
  4. [4] Aarhus University Hospital
    5. [NORA names: Central Denmark Region; Hospital; Denmark; Europe, EU; Nordic; OECD];
  5. [5] Department of Pathology, University Hospital Zealand, Roskilde, Denmark
    6. [NORA names: Denmark; Europe, EU; Nordic; OECD]

Keywords

carcinoma patients, cell carcinoma patients, chemo-, chemo- and immunotherapy, esophageal squamous cell carcinoma patients, first-line treatment, immunotherapy, patients, squamous cell carcinoma patients, standard treatment, trastuzumab, treatment, trials

Funders

  • Danish Cancer Society

Data Provider: Digital Science

LINKS
-

Matching Records in NORA

  • No Matches Found

SUBJECTS
+

METRICS
+